Lexapro Heart Rhythm Problems Draw New Warnings in Canada

Staff Writers

Add Your Comments

Health Canada has announced new warnings about a dose-related risk of abdnormal hearth rhythms from Lexapro, which is marketed as Cipralex in that country.

Lexapro contains the active pharmaceutical ingredient escitalopram, which is used to treat depression and belongs to the popular family of antidepressants known as serotonin reuptake inhibitors (SSRI).

According to information released today by Health Canada, labeling for the Canadian version of the drug, Cipralex, will be updated based on clinical trial data that have shown escitalopram may cause electrical changes in the heart, known as QT interval prolongation, which could lead to serious and potentially life-threatening abnormal heart rhythms.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

The risk of these heart rhythm problems from Lexapro and Cipralex appears to be dose-related, according to Health Canada, meaning that that the risk increases as the dosage increases.

New warnings about the risk of QT interval prolongation will be added to the label of Cipralex in Canada, as well as recommendations that the drug should not be used by individuals with a heart condition known as congenital long QT syndrome or with known QT interval prolongation. According to the warnings, use of the antidepressant should also be discouraged among individuals who are also taking other drugs that are known to prolong QT interval, such as certain medications to treat heart rhythm problems, certain antipsychotics, antidepressants, opioid painkillers and some medications prescribed to treat infections.

The maximum recommended dose has been limited to 10mg per day for certain at-risk patients, such as those 65 years old or older, with known liver problems or taking the heartburn drugs omeprazole or cimetideine, which may increase the blood level of escitalopram. For most other patients, the recommended maximum dose in Canada remains 20 mg per day.

Escitalopram was introduced in the United States in August 2002, under the brand name Lexapro, for treatment of major depression and generalized anxiety disorder. The medication has similar pharmacology to citalopram, which is marketed under the brand name Celexa in the United States.

In August 2011, the FDA issued a drug safety communication warning that side effects of Celexa may cause abnormal heart rhythms at high doses.

Tags: Celexa, Heart Rhythm, Lexapro, QT Prolongation

More Lawsuit Stories

1 Comments

Gonzalo
I started having sharp pains around my heart when I first got on Lexapro. weeks later was told I had asthma , Mitral valve prolapse and now having Fibromyalgia symptoms . Lexapro has ruined my life.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Depo-Provera Meningioma Warning Update Should Be Added to Birth Control Shot Lawsuit
A Depo-Provera meningioma lawsuit argues that Pfizer had a duty to warn women about scientific evidence linking the birth control shot to potential brain tumor growth yet failed to do so.
Judges Will Consider MDL for Dupixent Cancer Lawsuits Late Next Month
A group of federal judges will determine whether all Dupixent cancer lawsuits should be formed into a multidistrict litigation, following oral arguments set for May 28.
MORE ABOUT: DUPIXENT LAWSUIT
SCS Injury Lawsuit Alleges Unlicensed Abbott Representatives Modified Device After Implantation
A product liability lawsuit alleges unlicensed Abbott representatives made real-time spinal cord stimulator programming decisions based on a Texas woman’s responses, improperly modifying the device and contributing to her injuries.